David A. Siegel Kymera Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 260,300 shares of KYMR stock, worth $9.19 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
260,300
Previous 336,300
22.6%
Holding current value
$9.19 Million
Previous $15.9 Million
34.21%
% of portfolio
0.03%
Previous 0.04%
Shares
13 transactions
Others Institutions Holding KYMR
# of Institutions
185Shares Held
65.5MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$243 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$212 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$187 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$182 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$182 Million3.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.93B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...